Guggenheim analyst Jason Cassorla raised the firm’s price target on Tenet Healthcare (THC) to $188 from $180 and keeps a Buy rating on the shares after the company reported “hefty” Q2 EBITDA upside and raised 2025 guidance by over 10% at the midpoint. The firm believes a normalized multiple on its estimated 2026 sensitivity baseline “suggests continued solid upside” in shares following an earnings reaction that it calls “well overblown.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $238 from $230 at UBS
- Tenet Healthcare price target raised to $225 from $210 at Morgan Stanley
- Strong Performance and Strategic Growth Drive Buy Rating for Tenet Healthcare
- Tenet Healthcare: Strategic Focus and Financial Performance Drive Buy Rating
- Tenet Healthcare Reports Strong Q2 2025 Earnings, Raises Outlook